In Journal of translational medicine
BACKGROUND : This study aimed to develop a radiogenomic prognostic prediction model for colorectal cancer (CRC) by investigating the biological and clinical relevance of intratumoural heterogeneity.
METHODS : This retrospective multi-cohort study was conducted in three steps. First, we identified genomic subclones using unsupervised deconvolution analysis. Second, we established radiogenomic signatures to link radiomic features with prognostic subclone compositions in an independent radiogenomic dataset containing matched imaging and gene expression data. Finally, the prognostic value of the identified radiogenomic signatures was validated using two testing datasets containing imaging and survival information collected from separate medical centres.
RESULTS : This multi-institutional retrospective study included 1601 patients (714 females and 887 males; mean age, 65 years ± 14 [standard deviation]) with CRC from 5 datasets. Molecular heterogeneity was identified using unsupervised deconvolution analysis of gene expression data. The relative prevalence of the two subclones associated with cell cycle and extracellular matrix pathways identified patients with significantly different survival outcomes. A radiogenomic signature-based predictive model significantly stratified patients into high- and low-risk groups with disparate disease-free survival (HR = 1.74, P = 0.003). Radiogenomic signatures were revealed as an independent predictive factor for CRC by multivariable analysis (HR = 1.59, 95% CI:1.03-2.45, P = 0.034). Functional analysis demonstrated that the 11 radiogenomic signatures were predominantly associated with extracellular matrix and immune-related pathways.
CONCLUSIONS : The identified radiogenomic signatures might be a surrogate for genomic signatures and could complement the current prognostic strategies.
Zhong Min-Er, Duan Xin, Ni-Jia-Ti Ma-Yi-di-Li, Qi Haoning, Xu Dongwei, Cai Du, Li Chenghang, Huang Zeping, Zhu Qiqi, Gao Feng, Wu Xiaojian
2022-Dec-08
Colorectal cancer, Intratumor heterogeneity, Prognosis, Radiogenomic, Signature
